CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the second quarter of 2022. With more than two thirds of patients recruited and a drop-out rate of under 5%, the study remains fully funded, and we remain confident of reporting topline…
Full PDFSolna, 23 June 2022. The Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) has resolved on a directed issue of 3,896,885 shares to Östersjöstiftelsen (ÖSS) following a request for conversion in accordance with convertible loan agreement between Asarina Pharma and ÖSS entered into in May 2021.
Full PDFPeter Nordkild, CEO: “Strong, steady progress best sums up Q1 2022. In a productive Quarter we have kept steadfastly to the recruitment goals of our phase IIa Tourette study, despite tail-end Covid-19 effects at our study sites. We firmly expect to continue to do so. The study remains fully funded. We remain confident of reporting…
Full PDFThe following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on 4 May 20022. The Annual General Meeting was carried out through advance voting (postal voting) only.
Full PDFPeter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patients with various neurological disorders. Topline data for our phase IIa study in Tourette are still expected in Q1 of 2023 and the study remains fully funded. We maintain our full focus on…
Full PDF